CRISPR THERAPEUTICS AG Shareholders' Equity
CRISPR THERAPEUTICS AG (CRSP) had Shareholders' Equity of $1.75 billion as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-03
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.75B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $1.81B.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.92B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.92B.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $1.75B 10-Q · filed 2026-08-03 |
| 2026-03-31 | $1.81B 10-Q · filed 2026-08-03 |
| 2025-12-31 | $1.92B 10-Q · filed 2026-08-03 |
| 2025-09-30 | $1.92B 10-Q · filed 2025-11-10 |
| 2025-06-30 | $1.71B 10-Q · filed 2026-08-03 |
| 2025-03-31 | $1.83B 10-Q · filed 2026-08-03 |
| 2024-12-31 | $1.93B 10-Q · filed 2026-08-03 |
| 2024-09-30 | $1.94B 10-Q · filed 2025-11-10 |
| 2024-06-30 | $1.98B 10-Q · filed 2025-11-10 |
| 2024-03-31 | $2.08B 10-Q · filed 2025-11-10 |
| 2023-12-31 | $1.88B 10-K · filed 2026-02-12 |
| 2023-09-30 | $1.73B 10-Q · filed 2024-11-05 |
| 2023-06-30 | $1.82B 10-Q · filed 2024-11-05 |
| 2023-03-31 | $1.85B 10-Q · filed 2024-11-05 |
| 2022-12-31 | $1.88B 10-K · filed 2026-02-12 |
| 2022-09-30 | $1.95B 10-Q · filed 2023-11-06 |
| 2022-06-30 | $2.09B 10-Q · filed 2023-11-06 |
| 2022-03-31 | $2.24B 10-Q · filed 2023-11-06 |
| 2021-12-31 | $2.40B 10-K · filed 2025-02-11 |
| 2021-09-30 | $2.51B 10-Q · filed 2022-11-01 |
| 2021-06-30 | $2.60B 10-Q · filed 2022-11-01 |
| 2021-03-31 | $1.81B 10-Q · filed 2022-11-01 |
| 2020-12-31 | $1.66B 10-K · filed 2024-02-21 |
| 2020-09-30 | $1.34B 10-Q · filed 2021-11-03 |
| 2020-06-30 | $910.67M 10-Q · filed 2021-11-03 |
| 2020-03-31 | $886.10M 10-Q · filed 2021-11-03 |
| 2019-12-31 | $939.42M 10-K · filed 2023-02-21 |
| 2019-09-30 | $591.88M 10-Q · filed 2020-10-28 |
| 2019-06-30 | $367.68M 10-Q · filed 2020-10-28 |
| 2019-03-31 | $379.81M 10-Q · filed 2020-10-28 |
| 2018-12-31 | $392.19M 10-K · filed 2022-02-15 |
| 2018-09-30 | $417.31M 10-Q · filed 2019-10-28 |
| 2018-06-30 | $265.15M 10-Q · filed 2019-10-28 |
| 2018-03-31 | $290.33M 10-Q · filed 2019-10-28 |
| 2017-12-31 | $187.83M 10-K · filed 2021-02-16 |
| 2017-09-30 | $178.96M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $197.80M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $215.18M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $232.85M 10-K · filed 2020-02-12 |
| 2016-09-30 | -$62.48M 10-Q · filed 2016-11-22 |
| 2015-12-31 | -$29.10M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |